As I see the bottom line, the market's first impression is what counts to send the SP through the roof at the get-go.
" clinical trials need to be successful in meeting their primary outcome for the drug/indication" as per the trial design and the continued hype surrounding the RRR for apabetalone.
IMO...Koo